Recently, S-adenosyl-L-methionine disulfate tosylate (SAMe-DT), independently developed by Shandong Freda Biotechnology Co., Ltd. (hereinafter refered to as Shandong Freda), has successfully completed FDA New Dietary Ingredient (NDI) notification, with the NDIN number being 1473, marking the ingredient’s compliance for entry into the U.S. dietary supplement market. CIRS Group provided full support throughout the notification process.

Recently, Enhe Aiju (Hangzhou) Science and Technology Co., Ltd. (Enhe Aiju) has completed the FDA GRAS notice for its self-developed zeaxanthin, produced via fermentation using production strain Yarrowia lipolytica CGMCC 39021 (GRN No. 1300). This is the world’s first high-concentration crystalline zeaxanthin product manufactured at commercial scale using cell factory technology to receive GRAS, fully under the support of CIRS Group.

Recently, Shandong Weiyan Biotechnology Co., Ltd. (“Shandong Weiyan”) achieved a milestone in its international compliance journey for its product, astaxanthin. With comprehensive professional support from CIRS Group, the company’s astaxanthin has been concluded by GRAS Panel as Generally Recognized as Safe (GRAS).

On February 5, 2026, China’s NHC issued the No.1 Announcement of 2026. 3’-SL was approved as a new food nutrition enhancer, becoming the third officially authorized human milk oligosaccharide (HMOs) following 2’-FL and LNnT.

Earlier in September 2025, Shandong Runhan Biotechnology Co., Ltd. (“Runhan”) achieved a milestone in its international compliance journey for its core product, GlcNac. With comprehensive professional support from CIRS Group and its U.S. subsidiary, the company’s GlcNac has been concluded by GRAS Panel as Generally Recognized as Safe (GRAS).

Recently, VDK’s synthetically produced β-carotene, manufactured using synthetic biology technology, obtained self-GRAS notification. This milestone signifies the product’s approval as a safe food ingredient for sale and use in the American market, providing crucial support for VDK’s global expansion strategy. This notification was fully supported by CIRS Group.

On September 12, 2025, the National Health Commission (NHC) of China updated the List of New Food Ingredients Terminated from Review, adding two entries of D-allulose. Among them, the D-allulose application submitted by Shandong Fuyang Biotechnology Co., Ltd. (hereinafter referred to as “Shandong Fuyang”), represented by CIRS Group, was included.

Recently, CIRS Group successfully assisted Penglai Marine in obtaining Self-GRAS Notice for its anhydrous magnesium citrate. It signifies that Penglai Marine’s anhydrous magnesium citrate may now be legally marketed and utilized as a safe food ingredient within the U.S. market, marking a significant step forward in Penglai Marine’s internationalization efforts.

Recently, Fushine successfully obtained the self-GRAS notification for its FuNext protein, with the support of CIRS food expert team. This achievement not only highlights the company's robust research and development capabilities, but also serves as further proof of CIRS’s professional service expertise.

Recently, Guilin Layn Natural Ingredients Corp. (hereinafter referred to as "Layn"), with the support of CIRS, received a "no questions" letter from the FDA for its enzymatically converted rebaudioside M2 (hereinafter referred to as RebM2). This indicates that RebM2 has been successfully notified under the FDA GRAS (Generally Recognized as Safe) notification program. The official FDA GRAS notification, unlike a self-affirmed GRAS, carries greater authority and market recognition.